Il National Institute of Allergy and Infectious Diseases (Niaid), one of the institutes belonging to the American NIH, has started the experimentation for a Vaccine against theinfluenza with a universal formula a mRNA. The tests, as reported by Ansa, will be carried out on fifty volunteers aged between 18 and 49 years. In a first phase, the most effective dosage will be defined and subsequently the new product will be compared with the seasonal quadrivalent vaccine currently in use to verify which of the two is better.
The new vaccine aims to stimulate a immunity lasting against the flu using a portion of a protein characteristic of flu viruses: l’emoagglutinina. It is composed of a very rapidly evolving portion and a more stable portion, which would appear to be common in several pathogens. It is on the latter that the serum will try to act and, for this reason, the protection should be more lasting, so as to avoid the annual booster.
Influenza vaccine with universal mRNA formula: experimentation begins, how it works
“And Vaccine universal againstinfluenza would be a major public health outcome and could eliminate both the need for annual seasonal flu vaccine development and the need for patients to get a flu shot every year,” he commented. Hugh Auchinclossthe lead researcher of the Niaid. The solution in question would avoid the need to carry out periodic serum administration campaigns. In fact, they do not always bear the hoped-for results, especially among patients most at risk.
The goal is to ensure that the population is always covered, even if only the experimental phase will be able to clarify the real duration of protection and the effectiveness of the vaccine. “Some strains of the virus of the flu have a significant pandemic potential. A universal flu vaccine could serve as an important line of defense against the spread of a future flu pandemic,” concluded the expert.
© breaking latest news